Slash Pine Allergy Shots: The Southeast Plantation Myth-Buster
Slash pine (Pinus elliottii) carpets Florida, Georgia, Alabama, and South Carolina in yellow pollen each March–April, yet Bucholtz 1985 found only 3.2% of pollen-sensitive patients test positive to Pinus. The real Southeast spring allergens — live oak (Quercus virginiana), bayberry (Myrica/Morella), and sweet gum — overlap slash pine season and are far more clinically relevant. Testing before pursuing SCIT is essential; no RCT exists for slash pine.
About Curex’s SCIT program
Curex’s at-home allergy shots (SCIT) are coming soon and focus on the most common environmental allergens:
- • Pollens — tree, grass, weed & ragweed
- • Pet dander — cat & dog
- • Dust mites
- • Molds — Alternaria & mold mix
Slash Pineis covered here for general education and may not be part of Curex’s current treatment set. Join the waitlist and our care team will help confirm your options.
Slash Pine Allergy Immunotherapy: How It Works
Allergy immunotherapy is the only long-term treatment that re-trains the immune system to stop overreacting to slash pine — rather than just masking symptoms with antihistamines or steroids. By gradually exposing the body to controlled doses of slash pine allergen, immunotherapy shifts the underlying allergic response and produces relief that often outlasts treatment by 7–10 years.
There are two evidence-based forms of slash pine immunotherapy used today, both built on the same desensitization principle but delivered very differently.
of sustained relief after a complete immunotherapy course — the only allergy treatment with proven long-term effect after stopping.
Allergy Shots (SCIT)
Weekly injections of slash pine extract in a clinic, escalating over 3–6 months until a maintenance dose is reached. Continued monthly for 3–5 years. Longest clinical track record for slash pine allergy.
- Strongest evidence base for severe and polysensitized patients
- Covered by most insurance plans
- Requires 50–100+ in-person clinic visits across the full course
- Or at home with no clinic visits— Curex’s Virtual Shot Room model delivers the same SCIT program with live video supervision by trained Curex clinical staff for the first injection from each new vial or concentration and restarts after gaps or reactions.
Allergy Drops / Tablets (SLIT)
Daily drops or dissolvable tablets containing slash pine extract, held under the tongue at home. Same desensitization principle, delivered without injections. WHO-recognized as an effective form of allergy immunotherapy since 2001.
- Taken at home — no weekly clinic trips, no needles
- Lower systemic reaction rate than allergy shots
- Curex offers prescription slash pine immunotherapy drops with allergist oversight
The rest of this page goes deep on allergen-specific immunotherapy with shots — protocol, efficacy data, side effects, and cost. If you’d rather skip the clinic and treat slash pine allergy with at-home drops, see how Curex sublingual immunotherapy compares below.
What is Slash Pine?
The biology, taxonomy, and clinical fingerprint of Slash Pine — the foundation of how SCIT targets it.
Slash pine (Pinus elliottii) plantations across 13 million acres of the coastal Southeast deposit visible yellow pollen in March–April — but clinical allergy rates remain low, with the concurrent live oak and bayberry seasons driving most spring rhinitis.
- Scientific name
- Pinus elliottii
- Family
- PinaceaePine family
- Type
- Conifer plantation tree pollen
- Native to
- Coastal plain of southeastern US — Florida, Georgia, Alabama, Mississippi, South Carolina
- Allergen proteins
- No IUIS-named allergen registered for Pinus elliottii; IgE-binding bands at 42 kDa and 6–8 kDa shared across Pinus genus (Gastaminza 2009)
- Particle size
- 60–80 μm (saccate, two air sacs)
- Avoidance difficulty
- Very difficult
How Slash Pine Allergy Presents
Symptoms by body system — useful for distinguishing Slash Pine sensitivity from overlapping allergies and infections.
Respiratory
- Nasal congestion and sneezing during March–April coastal-plain pollen events
- Runny nose coinciding with visible yellow pine dust on cars and outdoor surfaces
- Mild asthma exacerbation in confirmed Pinus-sensitized individuals
- Prolonged symptom burden often attributable to overlapping live oak and bayberry seasons
Ocular
- Itchy, watery eyes during peak March–April pollen events
- Conjunctival redness from sustained outdoor exposure in plantation areas
- Mild eyelid swelling in sensitized individuals
Dermal
- Contact urticaria from direct pollen contact in high-density plantation settings (uncommon)
- Pine resin contact dermatitis — distinct from IgE-mediated pollen allergy
- Mild skin itching from outdoor exposure during peak pollen deposition
Systemic
- Fatigue from disrupted sleep during the extended Southeast pollen season
- Reduced outdoor activity tolerance in heavy-plantation coastal-plain communities
- Symptom misattribution — live oak and bayberry overlap slash pine timing and are more clinically significant
Every March in Jacksonville and Tallahassee the cars turn yellow and patients call asking for pine allergy shots. We test, and nine times out of ten the real culprit is live oak or bayberry. The yellow on the car is mostly cosmetic — the inflammation comes from something else blooming at the same time.
When & Where Slash Pine Peaks
Allergen intensity by month and by state. Useful for timing SCIT start dates and travel planning.
12-Month Intensity
Peak: March–April in the coastal plain; NAB Tampa and Jacksonville stations log counts >1,000 grains/m³· Approximately 8–10 weeks in the Southeast; longer warm-season duration than northern pines
US Exposure Map
5 high-intensity statesExposure intensity by state (text version)
- ME:
- Low
- VT:
- Low
- NH:
- Low
- WA:
- Low
- MT:
- Low
- ND:
- Low
- MN:
- Low
- WI:
- Low
- MI:
- Low
- NY:
- Low
- MA:
- Low
- OR:
- Low
- ID:
- Low
- WY:
- Low
- SD:
- Low
- IA:
- Low
- IL:
- Low
- IN:
- Low
- OH:
- Low
- PA:
- Low
- NJ:
- Low
- CT:
- Low
- RI:
- Low
- CA:
- Low
- NV:
- Low
- UT:
- Low
- CO:
- Low
- NE:
- Low
- MO:
- Low
- KY:
- Low
- WV:
- Low
- VA:
- Low
- MD:
- Low
- DE:
- Low
- AZ:
- Low
- NM:
- Low
- KS:
- Low
- AR:
- Low
- TN:
- Low
- NC:
- Moderate
- SC:
- High
- OK:
- Low
- LA:
- Moderate
- MS:
- High
- AL:
- High
- GA:
- High
- TX:
- Moderate
- FL:
- High
- AK:
- Low
- HI:
- Low
What Slash Pine Cross-Reacts With
Patients sensitized to one allergen often react to others sharing similar proteins. This map shows the documented molecular overlaps.
Slash pine shares near-complete IgE cross-reactivity with all Pinus species, but does not cross-react with Cupressaceae — an important distinction for Southeast patients who may confuse pine season with concurrent mold or other tree exposures.
Near-complete intra-Pinus cross-reactivity; loblolly and slash overlap geographically in the Carolinas
Is SCIT Right for Your Slash Pine Allergy?
Answer five questions to assess whether slash pine allergy shots are the right immunotherapy target for your Southeast spring symptoms.
How severe are your spring pollen symptoms during March–April in the Southeast?
The Slash Pine SCIT Protocol
Slash pine SCIT follows the standard inhalant build-up schedule with a non-standardized extract; your allergist may include slash pine in a multi-species southeastern pine mix rather than as a single-species vial.
Weekly injections escalate the slash pine extract concentration over 16–24 weeks. Your allergist calibrates starting dose based on skin-test reactivity to the non-standardized extract. A 30-minute observation period after every injection is mandatory.
At the target maintenance dose, injections shift to a maintenance schedule individualized by your allergist. Lot-to-lot variability in non-standardized pine extracts may prompt dose adjustment when new vials arrive. Symptom diary review at 12 months assesses clinical response.
After completing a full course, some patients achieve durable tolerance and discontinue; others continue. No slash pine-specific data inform this decision — it is based on clinical response.
Extract Concentration Ladder
You progress through each vial during build-up. Concentration increases ~10x per step.
What the Research Shows for Slash Pine SCIT
No randomized controlled trial has been published for slash pine SCIT — the evidence rests on observational data and extrapolation from the inhalant SCIT class, alongside the foundational pollen-immunology studies.
- Pinus sensitization in unselected pollen-allergic patients3%Bucholtz GA et al., J Allergy Clin Immunol, 1985, N=155
- IgE positivity in selected pine-allergic cohort69%Gastaminza G et al., Clin Exp Allergy, 2009, N=selected cohort
- Inhalant SCIT symptom reduction (class-level)60%Cox L et al., JACI, 2011 — AAAAI Practice Parameter meta-summary
No RCT has specifically studied slash pine SCIT. Bayberry (Morella cerifera) allergy was confirmed as a true Southeast aeroallergen by Jacinto et al. (JACI, 1992) with positive bronchial challenges — whereas pine lacks equivalent clinical proof of concept. Testing before SCIT initiation prevents years of treatment aimed at the wrong allergen.
Ready to skip the surprise bills?
At-home allergy shots (SCIT) are designed by board-certified allergists. See the listed SCIT plan rate in our pricing record and request a quote for eligibility, initiation and total care costs.
- MD-ledBoard-certified allergists
- QuoteTotal care estimate
- 50K+Patients treated
- HSA/FSAEligible
Slash Pine SCIT Side Effects
Slash pine SCIT carries the standard inhalant SCIT side-effect profile, with the same lot-to-lot variability caution as all non-standardized pine extracts.
Local reactions
3 documented| Reaction | Rate | Severity |
|---|---|---|
Injection-site swelling Most common; typically resolves within hours | Rate 30–50% | Mild |
Injection-site redness and itching More frequent at each new concentration step | Rate 20–40% | Mild |
Large local reaction (>5 cm) Not predictive of systemic reaction; may prompt dose reduction | Rate 5–15% | Moderate |
Systemic reactions
3 documented| Reaction | Rate | Severity |
|---|---|---|
Generalized urticaria Requires epinephrine and extended observation | Rate <1% | Moderate |
Rhinitis or conjunctivitis flare Temporary post-injection exacerbation of nasal or eye symptoms | Rate 1–3% | Mild |
Anaphylaxis A 30-minute self-observation accompanies every injection; with Curex the first injection from each new vial or concentration is supervised live in the Virtual Shot Room with a prescribed epinephrine auto-injector confirmed on hand | Rate <0.01% per injection | Severe |
The mandatory 30-minute post-injection observation period is a non-negotiable AAAAI safety standard. No deaths from properly supervised SCIT have been reported in the US in the past decade with adherence to these protocols.
SCIT vs Alternatives for Slash Pine
For Southeast patients with confirmed slash pine sensitization, allergy shots (SCIT) — now available as an at-home weekly injection with Curex — sublingual drops, avoidance, and daily medications are the main options, each with different tradeoffs for coastal-plain populations with long pollen seasons.
| Criterion | SCITBest | SLIT | Avoidance | Medications |
|---|---|---|---|---|
| Effectiveness | Moderate (no RCT; inhalant class extrapolation) | Emerging; no slash pine-specific trial | Limited — plantation pollen is unavoidable | Symptomatic relief only |
| 5-yr cost | $3,500–$15,000 | Varies by provider; sold as a general sublingual modality, not Curex's product | Low | $500–$2,000/year |
| Duration | 3–5 years | 3–5 years | Ongoing | Indefinite |
| Convenience | At-home weekly self-injection with Curex during build-up; the first injection from each new vial or concentration supervised live in the Virtual Shot Room | Daily drops at home | HEPA filters, windows closed March–April | Daily pills/sprays |
| Safety | USP <797> sterile-compounded serum, Virtual Shot Room–supervised dosing, prescribed epinephrine on hand, 30-min self-observation | Lower systemic reaction risk vs SCIT | Safe | Safe; antihistamine sedation risk |
| Lasting effect | Possible lasting tolerance | Possible lasting benefit | No immune modification | No lasting effect |
SCITBest
SLIT
Avoidance
Medications
For Southeast patients with confirmed slash pine sensitization who face a long seasonal burden, Curex now delivers the allergy shot itself at home with pricing confirmed in a current program quote — the serum sterile-compounded to USP <797>, a prescribed epinephrine auto-injector confirmed on hand, and the first injection from each new vial or concentration supervised live in the Virtual Shot Room — removing the extended weekly clinic-visit schedule that the Southeast's warm-season build-up period once required.
What Slash Pine SCIT Actually Costs
Most major insurers cover inhalant SCIT under standard allergy benefits when ordered by a board-certified allergist with documented pine-specific sensitization. Slash pine extract is non-standardized; prior authorization may be required. Verify coverage for CPT 95165 extract preparation before starting. Curex at-home IgE testing identifies specific slash pine sensitization before allergist consultations, eliminating the need for an initial skin-test visit.
Cost range varies by deductible, co-insurance, and clinic.
Verify these codes with your insurer to confirm coverage.
See the listed Environmental Allergy Shots Plan rate, commercial terms dated 2026-10-12; consultations are included without copay. Confirm availability, eligibility, other included services, testing, any in-person care, insurance responsibility and billing cadence in your written quote before enrolling.
Join the waitlistStop guessing about your slash pine allergy. Get a plan.
Take Curex’s 3-minute allergy quiz. A board-certified allergist will review your symptoms and recommend the right immunotherapy path for you — shots or drops.
Free quiz · Board-certified allergists · 50,000+ patients treated · HSA/FSA eligible
Slash Pine SCIT — Frequently Asked
Quick answers to the questions patients ask most before starting treatment.
The visible yellow coating on cars and outdoor surfaces in coastal Southeast cities in March–April is predominantly slash pine (Pinus elliottii) pollen — it is real, abundant, and measurable at counts exceeding 1,000 grains/m³ at NAB Tampa and Jacksonville stations. However, abundant pollen does not equal high allergenicity. Bucholtz et al. (J Allergy Clin Immunol, 1985) found only 3.2% of pollen-sensitive patients tested positive to Pinus in an unselected cohort. Most patients reacting to the March–April Southeast season are sensitized to concurrently blooming live oak, bayberry, or sweet gum — not the pine that coats their car.
Live oak (Quercus virginiana) and bayberry (Morella cerifera, formerly Myrica cerifera) are the dominant spring tree allergens in coastal Florida and Georgia. Bayberry's clinical relevance as a true aeroallergen was established by Jacinto et al. (J Allergy Clin Immunol, 1992) with positive bronchial challenges in sensitized patients — equivalent evidence does not exist for slash pine. Live oak overlaps with slash pine's March–April season across the entire coastal plain. A targeted Southeast spring tree panel including live oak, bayberry, sweet gum, and slash pine gives the complete picture.
No randomized controlled trial exists for slash pine (Pinus elliottii) SCIT. The general inhalant SCIT evidence supports benefit for confirmed sensitization, and Gastaminza et al. (Clin Exp Allergy, 2009) identified IgE-binding bands at 42 kDa and 6–8 kDa across Pinus species. However, without pine-specific trial data, efficacy cannot be quantified. A board-certified allergist should weigh this uncertainty — and confirm that pine is genuinely the primary sensitizer, rather than the more allergenic overlapping species — before prescribing a multi-year SCIT course.
From an immunologic standpoint, slash pine (Pinus elliottii) and loblolly pine (Pinus taeda) are nearly identical — both share the same IgE-binding bands at 42 kDa and 6–8 kDa and cross-react completely within the Pinus genus (Gastaminza 2009). The key difference is geographic distribution: slash pine dominates the coastal plain wetlands of Florida, southern Georgia, Alabama, and Mississippi, while loblolly is the dominant plantation pine of the Piedmont from the Carolinas through Virginia and eastern Texas. Both are included in southeastern pine-mix vials, and both have the same evidence gap (no SCIT RCT).
Yes — antihistamines can be taken during slash pine SCIT and are often recommended to reduce local injection-site reactions. Many Southeast allergists recommend taking an antihistamine 30–60 minutes before each injection visit. Antihistamines do not interfere with the immunologic mechanism of SCIT, which works through T-cell tolerance and IgG4 class-switching. During the Southeast's long warm pollen season, patients may find daily antihistamine use beneficial. Discuss timing and specific antihistamine choice with your prescribing allergist.
Most major US health insurers cover inhalant subcutaneous immunotherapy under standard allergy benefits when ordered by a board-certified allergist with documented sensitization. Because slash pine extract is non-standardized, some plans in Florida and Georgia require prior authorization and documented clinical necessity via skin prick test or ImmunoCAP results. CPT codes 95115, 95117, and 95165 are standard. Contact your insurer before starting SCIT to confirm coverage and whether your allergist is in-network — specialty access varies significantly across coastal-plain regions.
If symptoms do not improve after 12 months of maintenance-dose slash pine SCIT, the most likely explanation is that pine was not the primary sensitizer. A board-certified allergist should reassess the full allergen panel — live oak or bayberry sensitization is common in the Southeast and may have been underweighted at initial testing. Options include adding the confirmed allergen to the SCIT mix, discontinuing pine if clinical benefit is absent, or transitioning to a different modality. Because no pine SCIT RCT exists, the response-assessment framework is based on clinical judgment and symptom diary review rather than validated outcome measures.
Children can receive inhalant SCIT for slash pine provided they meet standard candidacy criteria: confirmed pine-specific IgE sensitization, inadequate symptom control with medications, and appropriate age (most allergists begin no earlier than age 5–6). For Southeast pediatric patients, the same evidence limitations apply as for adults — no RCT data and non-standardized extract. A pediatric allergist should review the full spring tree panel including live oak and bayberry before prescribing pine SCIT, to ensure the immunotherapy target correctly reflects the child's actual sensitization profile. On the safety side, a large safety study of self-administered allergen immunotherapy (Schaffer et al., 2015) found a systemic reaction rate of just 0.16% per patient across 23,614 patients and 2,021,600 injections, with no fatalities — lower than the 3%–14% typically seen with office-based shots. Note: Curex's at-home pilot is currently open to patients age 12 and older; pediatric patients require a trained adult caregiver physically present for every injection.
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.
Questions about Curex itself?
Straight answers about the company, the evidence, what patients report, and what it costs — including the parts that are not flattering.